Short Interest in Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Declines By 91.5%

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 4,700 shares, a drop of 91.5% from the January 31st total of 55,100 shares. Based on an average daily trading volume, of 56,600 shares, the short-interest ratio is presently 0.1 days.

Enzon Pharmaceuticals Stock Up 10.0 %

OTCMKTS:ENZN traded up $0.01 during trading hours on Friday, reaching $0.11. 131,635 shares of the company’s stock were exchanged, compared to its average volume of 106,177. The company has a market capitalization of $8.16 million, a P/E ratio of 11.01 and a beta of 0.26. Enzon Pharmaceuticals has a 12 month low of $0.06 and a 12 month high of $0.24. The business’s 50-day simple moving average is $0.15 and its two-hundred day simple moving average is $0.13.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.